Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis DOI Creative Commons
Paula Jhoana Escobedo-Aedo, Chris Serrand, Sarah Kabani

и другие.

Journal of Eating Disorders, Год журнала: 2025, Номер 13(1)

Опубликована: Март 17, 2025

Eating disorders (EDs) significantly impair physical health and psychosocial functioning. Few effective therapeutic approaches exist for EDs, particularly in Anorexia Nervosa (AN). The use of ketamine, already characterized as a noncompetitive NMDA antagonist anesthetic depression suicidal ideations, could be an innovative adjuvant treatment the AN spectrum. We describe case series eight patients treated with intravenous Ketamine Adjuvant Treatment (KAT) combined usual care. also review literature discuss theoretical mechanisms behind influence KAT EDs. Our were all female, diagnosis spectrum, aged between 16 44. offered attempting to remodel rigid food-centered thoughts. Some sessions guided by psychomotor or psychological support, thus working on self-image, body perceptions, self-esteem, sensorial re-exposure "forbidden" food. improved BMI, coefficient 0.71 (0.23–1.20, p = 0.002), tendency improve weight regain dynamics from fourth fifth infusion onwards. It reduce psychopathology obsessive-compulsive-like symptoms (ruminations, cognitive rigidity, guilt), improving clinical evolution. findings underscore potential approach restrictive EDs after failure first-line treatments. addresses thought patterns neurocognitive biases that are notoriously difficult target. Ketamine's "pro-plasticity" "pro-neurogenesis" properties may facilitate this effect. represents tool Future research controlled studies is imperative corroborate its

Язык: Английский

Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis DOI Creative Commons
Paula Jhoana Escobedo-Aedo, Chris Serrand, Sarah Kabani

и другие.

Journal of Eating Disorders, Год журнала: 2025, Номер 13(1)

Опубликована: Март 17, 2025

Eating disorders (EDs) significantly impair physical health and psychosocial functioning. Few effective therapeutic approaches exist for EDs, particularly in Anorexia Nervosa (AN). The use of ketamine, already characterized as a noncompetitive NMDA antagonist anesthetic depression suicidal ideations, could be an innovative adjuvant treatment the AN spectrum. We describe case series eight patients treated with intravenous Ketamine Adjuvant Treatment (KAT) combined usual care. also review literature discuss theoretical mechanisms behind influence KAT EDs. Our were all female, diagnosis spectrum, aged between 16 44. offered attempting to remodel rigid food-centered thoughts. Some sessions guided by psychomotor or psychological support, thus working on self-image, body perceptions, self-esteem, sensorial re-exposure "forbidden" food. improved BMI, coefficient 0.71 (0.23–1.20, p = 0.002), tendency improve weight regain dynamics from fourth fifth infusion onwards. It reduce psychopathology obsessive-compulsive-like symptoms (ruminations, cognitive rigidity, guilt), improving clinical evolution. findings underscore potential approach restrictive EDs after failure first-line treatments. addresses thought patterns neurocognitive biases that are notoriously difficult target. Ketamine's "pro-plasticity" "pro-neurogenesis" properties may facilitate this effect. represents tool Future research controlled studies is imperative corroborate its

Язык: Английский

Процитировано

0